NASDAQ:INM InMed Pharmaceuticals (INM) Stock Price, News & Analysis $1.38 -0.01 (-0.72%) As of 11:37 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About InMed Pharmaceuticals Stock (NASDAQ:INM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get InMed Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.38▼$1.4050-Day Range$1.28▼$1.8552-Week Range$0.58▼$2.50Volume12,232 shsAverage Volume919,546 shsMarket Capitalization$4.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview InMed Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products based on rare cannabinoids. The company combines cannabinoid science with drug-development expertise to investigate potential treatments for diseases with significant unmet medical needs. Its research pipeline has included INM-901, an investigational rare-cannabinoid therapy being developed for Alzheimer’s disease, as well as earlier programs targeting conditions such as epidermolysis bullosa and glaucoma. InMed also develops proprietary cannabinoid formulations and drug-delivery approaches intended to improve the therapeutic potential of cannabinoid-based medicines. In 2022, InMed acquired BayMedica, a producer of rare cannabinoids, expanding its capabilities in cannabinoid development and commercialization. The company is headquartered in Vancouver, British Columbia, and serves the global pharmaceutical and biotechnology markets through its research, development and specialty cannabinoid activities. InMed is led by Chief Executive Officer Eric A. Adams.AI Generated. May Contain Errors. Read More InMed Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreINM MarketRank™: InMed Pharmaceuticals scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingInMed Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageInMed Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about InMed Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of InMed Pharmaceuticals is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InMed Pharmaceuticals is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInMed Pharmaceuticals has a P/B Ratio of 4.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about InMed Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.94% of the float of InMed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverInMed Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InMed Pharmaceuticals has recently decreased by 57.52%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInMed Pharmaceuticals does not currently pay a dividend.Dividend GrowthInMed Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentInMed Pharmaceuticals has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for InMed Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for INM on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat Follows1 people have added InMed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership3.8 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of InMed Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $128,211.00 in company stock, which represents 2.8035% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, InMed Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $128,211.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders0.85% of the stock of InMed Pharmaceuticals is held by insiders.Percentage Held by Institutions20.12% of the stock of InMed Pharmaceuticals is held by institutions.Read more about InMed Pharmaceuticals' insider trading history. Receive INM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INM Stock News HeadlinesInMed Pharmaceuticals: InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity ComplianceSeptember 19, 2026 | finanznachrichten.deAdar1 Capital Management, Llc Buys 8,340 Shares of InMed Pharmaceuticals (NASDAQ:INM) StockSeptember 17, 2026 | insidertrades.comWall Street Legend: “I've discovered a fatal flaw built into Elon's AI model”Wall Street veteran Marc Chaikin says he's found a fatal flaw built into Elon Musk's AI model and every frontier AI system on earth today. In rural Tennessee, the U.S. government is racing to build what Chaikin calls Sovereign AI, a shift he believes could spark a $248 trillion market, 56 times larger than today's AI industry.September 24 at 1:00 AM | Chaikin Analytics (Ad)InMed Pharmaceuticals (INM) Expected to Announce Quarterly Earnings on WednesdaySeptember 16, 2026 | americanbankingnews.comInMed Pharmaceuticals Inc. (NASDAQ:INM) Sees Large Decline in Short InterestSeptember 13, 2026 | americanbankingnews.comInMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine PipelineJuly 22, 2026 | benzinga.comMentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention PipelineJuly 22, 2026 | prnewswire.comInMed Pharmaceuticals Inc.June 29, 2026 | barrons.comSee More Headlines INM Stock Analysis - Frequently Asked Questions How have INM shares performed this year? InMed Pharmaceuticals' stock was trading at $1.06 at the beginning of the year. Since then, INM shares have increased by 30.2% and is now trading at $1.38. How were InMed Pharmaceuticals' earnings last quarter? InMed Pharmaceuticals Inc. (NASDAQ:INM) issued its quarterly earnings data on Wednesday, September, 9th. The company reported ($1.43) earnings per share for the quarter. When did InMed Pharmaceuticals' stock split? Shares of InMed Pharmaceuticals reverse split on Wednesday, September 7th 2022.The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are InMed Pharmaceuticals' major shareholders? InMed Pharmaceuticals' top institutional shareholders include Montanova Capital LLC (3.02%). Insiders that own company stock include Adar1 Capital Management, Llc, Vivo Opportunity, Llc, Eric A Adams and Andrew Hull. View institutional ownership trends. How do I buy shares of InMed Pharmaceuticals? Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of InMed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that InMed Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Tesla (TSLA) and PayPal (PYPL). Company Calendar Last Earnings9/09/2026Today9/24/2026Next Earnings (Estimated)11/05/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 INM's financial health is in the Green zone, according to TradeSmith. INM has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:INM CIK1728328 Webwww.inmedpharma.com Phone604-669-7207FaxN/AEmployees6Year Founded2014Profitability EPS (Trailing Twelve Months)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.56 million Net MarginsN/A Pretax Margin-992.97% Return on Equity-156.08% Return on Assets-123.90% Debt Debt-to-Equity RatioN/A Current Ratio1.37 Quick Ratio1.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book4.31Miscellaneous Outstanding Shares3,314,000Free Float3,286,000Market Cap$4.57 million OptionableNot Optionable Beta0.98 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:INM) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersThe AI Infrastructure Rush Is ON — Watch VDTAVertical Data Inc. (OTCQB: VDTA) is targeting the layers beneath the AI boom - GPU hardware and financing, man...Trading Wire | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredThe Pentagon Has 120 Days to Solve This Critical Mineral ProblemChina controls roughly 80% of the world's tungsten supply, and new Pentagon sourcing restrictions take effect ...The Tomorrow Investor | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWall Street Legend: “I've discovered a fatal flaw built into Elon's AI model”Wall Street veteran Marc Chaikin says he's found a fatal flaw built into Elon Musk's AI model and every fronti...Chaikin Analytics | SponsoredArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INM Stock Alerts